Want to see HK:0897 full AI Analyst Report?
0897 Stock Chart & Stats
HK$0.36
>-HK$0.01(-1.67%)
At close: 4:00 PM EST
HK$0.36
>-HK$0.01(-1.67%)
Day’s Range― - ―
52-Week RangeHK$0.27 - HK$0.51
Previous CloseN/A
Volume490.00K
Average Volume (3M)197.23K
Market Cap
HK$373.32M
Enterprise ValueHK$560.58
Total Cash (Recent Filing)HK$147.44M
Total Debt (Recent Filing)HK$279.29M
Price to Earnings (P/E)94.4
Beta0.40
Next Earnings
Dec 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield84.69%
Share Statistics
EPS (TTM)<0.01
Shares Outstanding1,114,382,900
10 Day Avg. Volume297,209
30 Day Avg. Volume197,231
Financial Highlights & Ratios
PEG Ratio-2.14
Price to Book (P/B)0.31
Price to Sales (P/S)0.54
P/FCF Ratio6.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sharp Debt ReductionSubstantial deleveraging reduces financial risk and interest-related pressure while improving flexibility for inventory, store investment, and other operating needs. A much stronger capital structure should make the business more resilient and provide greater room to manage future changes in demand.
Positive Operating And Free Cash FlowPositive operating and free cash flow show that the retail and distribution model is generating cash despite very thin reported earnings. This supports ongoing operations and gives management internally generated resources, reducing reliance on borrowing to fund the business.
Improved Gross Margin And Positive Net IncomeThe higher gross margin indicates improved economics at the product level, while two consecutive years of positive net income mark progress from earlier loss periods. If maintained, this combination can strengthen earnings quality and support gradual recovery in overall profitability.
Bears Say
Multi-year Revenue ContractionPersistent revenue decline signals weakening sales scale across the company’s retail and distribution activities. Lower volume can reduce operating leverage, limit the ability to spread fixed costs, and make sustained earnings improvement difficult unless the group restores durable demand growth.
Very Thin Profitability And Negative Operating ProfitVery low net margins leave limited protection against cost increases or weaker sales, while negative operating profit shows that core operations are not yet covering all operating costs. This constrains the durability of earnings and raises the risk that small revenue changes materially affect results.
Weaker And Volatile Cash-flow MomentumAlthough cash generation remains positive, the sharp year-over-year fall in free cash flow and historical volatility reduce confidence that current cash conversion is repeatable. Less consistent internally generated cash can constrain investment capacity and make financial planning more difficult.
Wai Yuen Tong Medicine Holdings Limited News
0897 FAQ
What was Wai Yuen Tong Medicine Holdings Limited’s price range in the past 12 months?
Wai Yuen Tong Medicine Holdings Limited lowest stock price was HK$0.27 and its highest was HK$0.51 in the past 12 months.
What is Wai Yuen Tong Medicine Holdings Limited’s market cap?
Wai Yuen Tong Medicine Holdings Limited’s market cap is HK$373.32M.
When is Wai Yuen Tong Medicine Holdings Limited’s upcoming earnings report date?
Wai Yuen Tong Medicine Holdings Limited’s upcoming earnings report date is Dec 01, 2026 which is in 75 days.
How were Wai Yuen Tong Medicine Holdings Limited’s earnings last quarter?
Wai Yuen Tong Medicine Holdings Limited released its earnings results on Jun 25, 2026. The company reported HK$0.001 earnings per share for the quarter.
Is Wai Yuen Tong Medicine Holdings Limited overvalued?
According to Wall Street analysts Wai Yuen Tong Medicine Holdings Limited’s price is currently Overvalued.
Does Wai Yuen Tong Medicine Holdings Limited pay dividends?
Wai Yuen Tong Medicine Holdings Limited pays a Notavailable dividend of HK$0.177 which represents an annual dividend yield of 84.69%. See more information on Wai Yuen Tong Medicine Holdings Limited dividends here
What is Wai Yuen Tong Medicine Holdings Limited’s EPS estimate?
Wai Yuen Tong Medicine Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Wai Yuen Tong Medicine Holdings Limited have?
Wai Yuen Tong Medicine Holdings Limited has 1,114,382,900 shares outstanding.
What happened to Wai Yuen Tong Medicine Holdings Limited’s price movement after its last earnings report?
Wai Yuen Tong Medicine Holdings Limited reported an EPS of HK$0.001 in its last earnings report. Following the earnings report the stock price went up 3.448%.
Which hedge fund is a major shareholder of Wai Yuen Tong Medicine Holdings Limited?
Currently, no hedge funds are holding shares in HK:0897
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Wai Yuen Tong Medicine Holdings Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.52%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.26%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Wai Yuen Tong Medicine Holdings Limited
Wai Yuen Tong Medicine Holdings Limited operates as an investment holding company with a multifaceted business portfolio. Its core activities encompass the production, processing, and retail distribution of traditional Chinese medicines, Western pharmaceuticals, and a range of health and personal care products. These offerings reach customers across Hong Kong, mainland China, Macau, and international markets. The company's Chinese medicine and health food lines are marketed under the Wai Yuen Tong brand, while its Western pharmaceutical and personal care items are available under the Madame Pearl's and Pearl's labels. Beyond its product-focused segments, the group also engages in property investment, ownership, and sales, provides financial services, and oversees an agricultural produce exchange. As of March 31, 2022, Wai Yuen Tong maintained 63 retail stores in Hong Kong. Founded in 1897, the company is headquartered in Kowloon Bay, Hong Kong, and operates as a subsidiary of Rich Time Strategy Limited.
Technical Analysis
China Traditional Chinese Medicine Holdings Co
―
Lee's Pharmaceutical Holdings Limited
―
PuraPharm Corp. Ltd.
―
Pak Fah Yeow International Limited
―
Golden Throat Holdings Group Co Ltd
―